These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 15504841)

  • 1. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
    Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
    Cha R; Rybak MJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.
    Sprandel KA; Schriever CA; Pendland SL; Quinn JP; Gotfried MH; Hackett S; Graham MB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4597-605. PubMed ID: 15561831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of antimicrobial activity of amoxicillin/clavulanic acid and metronidazole against beta-lactamase-producing Bacteroides fragilis group.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; Muñoz-Bellido JL
    J Chemother; 1990 Feb; 2(1):11-6. PubMed ID: 2332779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
    Schaumann R; Petzold S; Fille M; Rodloff AC
    Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of an ofloxacin-metronidazole combination against anaerobic bacteria. Kinetics of the action of metronidazole against Bacteroides fragilis].
    Dubreuil L; Devos J; Beerens H; Romond C
    Pathol Biol (Paris); 1988 May; 36(5):488-92. PubMed ID: 3043345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection.
    Lewis RE; Klepser ME; Ernst EJ; Snabes MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 May; 37(1):51-5. PubMed ID: 10794941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear models for in vitro kill kinetics of antibiotics.
    Lee ML; DuBois A; Ross RA; Onderdonk AB
    J Biopharm Stat; 1999 May; 9(2):271-7. PubMed ID: 10379693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
    Stearne LE; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3605-11. PubMed ID: 17646416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
    Noel AR; Bowker KE; Macgowan AP
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
    Agudelo M; Vesga O
    Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I; Cars O; Löwdin E
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics/pharmacodinamic (PK/PD) evaluation of a short course of oral administration of metronidazole for the management of infections caused by Bacteroides fragilis].
    Morales-León F; von Plessing-Rossel C; Villa-Zapata L; Fernández-Rocca P; Sanhueza-Sanhueza C; Bello-Toledo H; Mella-Montecinos S
    Rev Chilena Infectol; 2015 Apr; 32(2):135-41. PubMed ID: 26065445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro.
    Karjagin J; Pähkla R; Karki T; Starkopf J
    J Antimicrob Chemother; 2005 Mar; 55(3):341-6. PubMed ID: 15728145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.